Latvian Institute of Organic Synthesis (LIOS) is a public research organisation and is the leading drug discovery and development centre in the Baltics.

The Institute of Organic Synthesis is involved in the fundamental studies in the field of organic (O-, S- and N-heterocycles, betaines), bioorganic (peptides, membrane active substances), organoelement (organic compounds of silicon, germanium, tin, metal complex catalysis) and physical organic chemistry (NMR, ESR, mass spectroscopy, X-ray structure analysis, electroanalytical chemistry).

The other direction of the Institute’s work is medicinal chemistry and drug development field. The Institute has developed 17 pharmaceuticals for the treatment of cancer, infectious, cardiovascular, and other diseases. The inventions of the Institute have been protected by around 60 patents.

At present the staff of the Latvian Institute of Organic Synthesis reaches 314 employees, including around 115 PhDs. Keeping up its best traditions the Institute continues to successfully combine its activities in the fundamental research and academic education with the development of new drugs for the industry.

LIOS joined the consortium in 2023 after a Hop-On application.

Role in the project

The Latvian Institute of Organic Synthesis (LIOS) will contribute to the project TransPharm with its experience in organic electrochemistry performing batch type and flow electrochemical reactions. This work complements nicely with the “greener production” module of the TransPharm value chain. The Development of electrochemical flow reactions and Electrochemical derivatization of platform molecules to access building blocks for API manufacturing will be tasks for LIOS. LIOS posses all the necessary infrastructure including the electrochemistry equipment.